Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
meeting entities : Rocket pharmaceuticals, inc. save search
Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Published: 2023-05-19 (Crawled : 12:20) - biospace.com/
RCKT 4 | $23.64 -0.13% -0.13% 920K
|
Health Technology
|
| O: 2.35%
H: 1.24%
C: 0.6%
positive cell pharmaceuticals meeting cardiovascular therapy
Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting
Published: 2022-12-22 (Crawled : 12:20) - biospace.com/
RCKT 4 | $23.64 -0.13% -0.13% 920K
|
Health Technology
|
| O: -9.24%
H: 1.19%
C: -5.14%
fda pharmaceuticals disease meeting update rp-a501 danon disease phase 1
Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting
Published: 2022-12-12 (Crawled : 18:00) - biospace.com/
RCKT 4 | $23.64 -0.13% -0.13% 920K
|
Health Technology
|
| O: 0.84%
H: 7.72%
C: 5.69%
pharmaceuticals meeting positive
Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa
Published: 2022-10-10 (Crawled : 13:00) - biospace.com/
RCKT 4 | $23.64 -0.13% -0.13% 920K
|
Health Technology
|
| O: -0.47%
H: 0.59%
C: -1.65%
pharmaceuticals meeting
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
Published: 2022-09-30 (Crawled : 11:00) - biospace.com/
RCKT 4 | $23.64 -0.13% -0.13% 920K
|
Health Technology
|
| O: 2.71%
H: 11.12%
C: 10.68%
america pharmaceuticals disease meeting heart trial positive rp-a501 danon disease phase 1
Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
Published: 2022-09-16 (Crawled : 13:00) - biospace.com/
RCKT 4 | $23.64 -0.13% -0.13% 920K
|
Health Technology
|
| O: -2.44%
H: 1.18%
C: -7.96%
america disease meeting heart trial rp-a501 danon disease phase 1
Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Published: 2022-05-19 (Crawled : 12:00) - biospace.com/
RCKT 4 | $23.64 -0.13% -0.13% 920K
|
Health Technology
|
| O: -1.95%
H: 5.37%
C: -0.5%
program positive therapy topline
Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Published: 2022-05-16 (Crawled : 12:00) - biospace.com/
RCKT 4 | $23.64 -0.13% -0.13% 920K
|
Health Technology
|
| O: 9.74%
H: 4.82%
C: -0.77%
anemia positive therapy danon disease
Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-13 (Crawled : 15:00) - biospace.com/
RCKT 4 | $23.64 -0.13% -0.13% 920K
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
treatment ema als anemia gene therapies positive gene therapy
Rocket Pharmaceuticals to Present at the 2021 Cell & Gene Meeting on the Mesa
Published: 2021-10-07 (Crawled : 12:00) - biospace.com/
RCKT 4 | $23.64 -0.13% -0.13% 920K
|
Health Technology
|
| O: 0.52%
H: 3.47%
C: 0.76%
Rocket Pharmaceuticals Presents Clinical Data from RP-A501 Trial in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021
Published: 2021-09-14 (Crawled : 12:00) - biospace.com/
RCKT 4 | $23.64 -0.13% -0.13% 920K
|
Health Technology
|
| O: -1.1%
H: 2.64%
C: -3.01%
disease heart trial rp-a501 danon disease
Rocket Pharmaceuticals Announces Upcoming Danon Disease Presentation at the Heart Failure Society of America Annual Scientific Meeting 2021
Published: 2021-09-10 (Crawled : 12:00) - biospace.com/
RCKT 4 | $23.64 -0.13% -0.13% 920K
|
Health Technology
|
| O: 1.02%
H: 2.15%
C: 1.49%
presentation disease heart danon disease
Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24th Annual Meeting of the American Society of Gene and Cell Therapy
Published: 2021-05-13 (Crawled : 12:00) - biospace.com/
RCKT 4 | $23.64 -0.13% -0.13% 920K
|
Health Technology
|
| O: 1.61%
H: 3.67%
C: -3.17%
positive therapy anemia
Rocket Pharmaceuticals Reports Positive Long-Term Clinical Data from RP-L201 Trial for the Treatment of Leukocyte Adhesion Deficiency-I at the Clinical Immunology Society 2021 Annual Meeting
Published: 2021-04-14 (Crawled : 12:00) - biospace.com/
RCKT 4 | $23.64 -0.13% -0.13% 920K
|
Health Technology
|
| O: 0.88%
H: 7.34%
C: 2.57%
treatment positive immunology trial
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.